{"symbol":"REGN","fiscalQuarter":"Q3-2017","reportDate":"2017-11-08","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2017","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.67%","keyNumbers":[{"metric":"EPS","actual":"$3.99","expected":"N/A","surprise":"+0.93%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our performance this quarter.","Our pipeline continues to show promise."],"summary":"Management expressed confidence in the company's current performance and future prospects. They highlighted the strength of their pipeline and ongoing projects."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong EPS, exceeding expectations, which contributed to a 2.67% increase in stock price. The lack of revenue data means investors will need to focus on other performance indicators. Management's positive tone suggests they are optimistic about future growth, particularly in their pipeline.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2017 earnings: EPS beat by 0.93%. Stock up 2.67%. Full breakdown."}}